41,334 results match your criteria neoadjuvant treatment

Surgical navigation for challenging recurrent or pretreated intra-abdominal and pelvic soft tissue sarcomas.

J Surg Oncol 2021 Jul 28. Epub 2021 Jul 28.

Department of Surgical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Background: This study assessed whether electromagnetic navigation can be of added value during resection of recurrent or post-therapy intra-abdominal/pelvic soft tissue sarcomas (STS) in challenging locations.

Materials And Methods: Patients were included in a prospective navigation study. A pre-operatively 3D roadmap was made and tracked using electromagnetic reference markers. Read More

View Article and Full-Text PDF

Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma.

J Hepatobiliary Pancreat Sci 2021 Jul 28. Epub 2021 Jul 28.

Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

Background: Development of a pragmatic pathologic classifier of pancreatic ductal adenocarcinoma (PDAC) that reflects biological behavior is needed.

Methods: The tumor epithelial and stromal features of PDAC and molecular subtype-related markers were evaluated in three independent cohorts.

Results: In the non-neoadjuvant therapy cohort (n=108), regarding tumor-epithelial feature, 'non-gland forming' type showed worse prognosis compared to 'gland forming' type (p<0. Read More

View Article and Full-Text PDF

Commentary: Anatomic resection after neoadjuvant TKI therapy-To be forewarned.

Andrew C Chang

JTCVS Tech 2021 Jun 2;7:298. Epub 2021 Mar 2.

Michigan Medicine, University of Michigan, Ann Arbor, Mich.

View Article and Full-Text PDF

The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma.

Oncotarget 2021 Jul 20;12(15):1490-1498. Epub 2021 Jul 20.

Pathology, The University of South Alabama, Mobile, AL, USA.

Introduction: Exosomes have pivotal roles in cancer development. The impact of neoadjuvant concurrent chemoradiation (NCCR) on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma are yet to be explored.

Materials And Methods: Between 2015 and 2018, 33 patients had rectal adenocarcinoma treated with NCCR and had pre-NCCR biopsy and post-NCCR resected rectum. Read More

View Article and Full-Text PDF

Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer.

Clin Cancer Res 2021 Jul 27. Epub 2021 Jul 27.

University of California San Francisco Medical Center.

Purpose: Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR) rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage triple-negative, and possibly high-risk estrogen receptor-positive breast cancer. However, immunotherapy has been associated with significant toxicity and most patients treated with NAC do not require immunotherapy to achieve pCR. Biomarkers discerning patients benefitting from the addition of immunotherapy from those who would achieve pCR to NAC alone are clearly needed. Read More

View Article and Full-Text PDF

Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy.

J Nanobiotechnology 2021 Jul 27;19(1):221. Epub 2021 Jul 27.

Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Background: Despite advances of surgery and neoadjuvant chemotherapy during the past few decades, the therapeutic efficacy of current therapeutic protocol for osteosarcoma (OS) is still seriously compromised by multi-drug resistance and severe side effects. Amplification of intracellular oxidative stress is considered as an effective strategy to induce cancer cell death. The purpose of this study was to develop a novel strategy that can amplify the intracellular oxidative stress for synergistic cascade cancer therapy. Read More

View Article and Full-Text PDF

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.

BMC Cancer 2021 Jul 27;21(1):862. Epub 2021 Jul 27.

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, China.

Background: Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer.

Methods: Postmenopausal women with ER-positive, HER2-negative breast cancer who had a primary tumor > 2 cm or positive axillary lymph node(s) proofed by biopsy were randomly (1,1) enrolled to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles before surgery. Primary outcome was feasibility of the trial. Read More

View Article and Full-Text PDF

Efficacy of Neoadjuvant Therapy in Improving Long-Term Survival of Patients with Resectable Rectal Cancer: A Meta-Analysis.

Anticancer Agents Med Chem 2021 Jul 26. Epub 2021 Jul 26.

Department of Anesthesiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.

Background: The impact of neoadjuvant therapy on long-term prognosis of patients with resectable rectal cancer is currently unknown.

Objective: This study aimed to explore the long-term prognosis of patients with resectable rectal cancer following treatment with neoadjuvant therapy.

Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to identify relevant articles published between January 2000 and July 2020. Read More

View Article and Full-Text PDF

One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.

Eur J Pharmacol 2021 Jul 24:174366. Epub 2021 Jul 24.

Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China; Cancer Center of Zhejiang University, Hangzhou, China. Electronic address:

Carboplatin treatment is associated with potential benefits in practice in the neoadjuvant chemotherapy for Triple-negative breast cancer (TNBC) patients. In order to enhance its anti-tumor effects, new concepts for successful combination therapy are needed. Here, we interestingly found that the combination treatment of carboplatin with the Chk1 inhibitor AZD7762 synergistically inhibits TNBC cell growth in multiple TNBC cell lines in vitro. Read More

View Article and Full-Text PDF

Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomy.

Int J Clin Oncol 2021 Jul 27. Epub 2021 Jul 27.

Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan.

Background: We investigated the association between positive surgical margin (PSM) status and biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) to develop a prognostic factor-based risk stratification model for BCR.

Methods: We analyzed the data of 483 patients who underwent RARP at our hospital between October 2010 and April 2019; 435 patients without neoadjuvant therapy were finally included. The BCR-free survival rate was determined using Kaplan-Meier analysis. Read More

View Article and Full-Text PDF

Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report.

AME Case Rep 2021 25;5:30. Epub 2021 Jul 25.

Department of Hematology/Oncology, Samuel Oschin Cancer Center, Los Angeles, CA, USA.

Immunotherapy has been established as a standard in select molecular subgroups of treatment-refractory advanced gastric cancer. However, its role in resectable gastric cancer where perioperative systemic therapy is the standard remains unclear. We present a case of a man who was diagnosed with resectable gastric cancer that was microsatellite stable but programmed death-ligand 1 (PD-L1) and Epstein-Barr Virus (EBV)-positive. Read More

View Article and Full-Text PDF

Prognostic significance of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients undergoing curative resection for colorectal cancer.

Ann Ital Chir 2021 ;92:283-292

Background/objective: In this study, we aimed to determine the relationship between HALP score and postoperative complications (According to Clavien-Dindo classification 3 and above), in patients with colo-rectal cancer who underwent curative surgical resection and to determine its clinical value in predicting prognosis.

Methods: 279 patients who underwent curative surgery for colorectal cancer between 2015-2018 were included in the study. The HALP value was calculated by dividing the product of hemoglobin (g/L), albumin (g/L), lymphocytes (/ L) by the number of platelets (/ L). Read More

View Article and Full-Text PDF
January 2021

The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review.

Curr Probl Cancer 2021 Jul 8:100765. Epub 2021 Jul 8.

Department of Urology, Pontifical Catholic University of Rio Grande do Sul, Brázil. Electronic address:

Therapies based on the use of immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab, ipilimumab, atezolizumab, avelumab, and durvalumab, have proven effective in the treatment of metastatic urological neoplasms. Recently, it has been hypothesized that the use of this type of treatment prior to surgery could lead to an increased difficulty in renal and bladder surgeries. The literature concerning this topic, however, is still scarce and non-consensual. Read More

View Article and Full-Text PDF

Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.

Gynecol Oncol 2021 Jul 23. Epub 2021 Jul 23.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Joan & Sanford I. Weill Medical College of Cornell University, New York, NY, USA. Electronic address:

Purpose: To determine the incidence of venous thromboembolism (VTE) and define clinical risk factors associated with the development of new-onset VTE in patients receiving neoadjuvant chemotherapy (NACT) for ovarian cancer (OC).

Methods: An institutional ovarian cancer database was used to identify all OC patients receiving NACT from 04/2015-09/2018. VTE events were recorded and included clinically diagnosed deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Read More

View Article and Full-Text PDF

ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy.

Ann Surg Oncol 2021 Jul 22. Epub 2021 Jul 22.

Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.

View Article and Full-Text PDF

Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer.

Int J Colorectal Dis 2021 Jul 22. Epub 2021 Jul 22.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Purpose: To compare the characteristics and outcomes of rectal cancer patients with local recurrence at a perianastomotic site (PA), a surgical field (SF) site, or in lateral lymph nodes (LLN).

Methods: A total of 114 consecutive patients who underwent surgery for recurrent, non-metastatic rectal cancer at a single comprehensive cancer center between 1997 and 2012 were grouped on the basis of radiographic assessment of type of recurrence: PA, 76 (67%) patients; SF, 25 (22%) patients; LLN, 13 (11%) patients. Demographic, clinical, and pathological features were compared between the three groups, as were disease-free survival (DFS) and overall survival (OS). Read More

View Article and Full-Text PDF

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.

J Exp Clin Cancer Res 2021 Jul 22;40(1):239. Epub 2021 Jul 22.

Institute of Experimental Endocrinology and Oncology "Gaetano Salvatore", CNR, Via S. Pansini 5, 80131, Naples, Italy.

Background: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy. Read More

View Article and Full-Text PDF

The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung adenocarcinoma has on T-stage and treatment.

Ann Diagn Pathol 2021 Jul 20;54:151799. Epub 2021 Jul 20.

Department of Pathology and Laboratory Medicine Rhode Island Hospital, The Warren Alpert School of Medicine, Brown University, United States of America. Electronic address:

Lung adenocarcinoma is currently staged based on invasive tumor size, excluding areas of lepidic (in situ) growth. Invasive tumor size may be determined by pathologic assessment of a surgical specimen or radiographic assessment on computerized tomography (CT) scan. When invasive tumor size is the primary stage determinate, radiographic-pathologic discordance or discordant interpretation among pathologists may alter tumor stage and treatment. Read More

View Article and Full-Text PDF

Treatment outcomes of patients with involved resection margin after rectal cancer surgery: A nationwide population-based cohort study in South Korea.

Asia Pac J Clin Oncol 2021 Jul 26. Epub 2021 Jul 26.

Division of Colon and Rectal Surgery, Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Background: The involvement of resection margins after rectal cancer surgery by malignant tumors is a negative prognostic factor. Therefore, it is important to analyze treatment outcomes and establish adjuvant therapy.

Methods: The Health Insurance Review and Assessment Service collects data from medical institutions in South Korea. Read More

View Article and Full-Text PDF

Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.

Cell Prolif 2021 Jul 26:e13102. Epub 2021 Jul 26.

Division of Regenerative Biology, School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.

Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in incidence during adolescence. Delayed patient presentation and diagnosis is common with approximately 15% of OS patients presenting with metastatic disease at initial diagnosis. With the introduction of neoadjuvant chemotherapy in the 1970s, disease prognosis improved from 17% to 60%-70% 5-year survival, but outcomes have not significantly improved since then. Read More

View Article and Full-Text PDF

Current status of systemic therapy in head and neck cancer.

J Chemother 2021 Jul 24:1-16. Epub 2021 Jul 24.

Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.

There are several controversies in the management of head and neck cancer (SCCHN). Although combined modality treatment is standard in locally advanced SCCHN (LA-SCCHN), the optimal timing of chemotherapy has been debated. Toxicity concerns with chemoradiation (CRT) using high dose cisplatin have prompted use of less intensive approaches. Read More

View Article and Full-Text PDF

Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis.

Acta Oncol 2021 Jul 24:1-9. Epub 2021 Jul 24.

Department of General Surgery, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdańsk, Poland.

Background: Short-course radiotherapy with consolidation chemotherapy (SCRT-CCT) has emerged as a promising alternative to the long course chemoradiotherapy (LCRT) regimen in locally advanced rectal cancer management. The systematic review and meta-analysis is aimed at summarizing current evidence on SCRT-CCT and comparing it to LCRT.

Material And Methods: Electronic databases of MEDLINE, Web of Science, and Cochrane library were searched using a predefined search strategy returning 3314 articles. Read More

View Article and Full-Text PDF

Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.

Technol Cancer Res Treat 2021 Jan-Dec;20:15330338211034291

Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.

Background: The objective of this study was to assess the prognostic value of pretreatment platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-white blood cell ratio (LWR) of CRC patients who received neoadjuvant chemotherapy.

Methods: We analyzed the peripheral blood routine parameters and other clinical data of 145 patients with colorectal cancer who had undergone neoadjuvant chemotherapy between January 2011 and February 2014. Pretreatment blood parameters of 145 patients were collected, and PLR, NLR, and LWR were calculated. Read More

View Article and Full-Text PDF

Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?

Mol Ther Oncolytics 2021 Sep 14;22:1-12. Epub 2021 May 14.

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, 420 Delaware St., SE, MMC 480, Minneapolis, MN 55455, USA.

Immunotherapy in the metastatic setting has drastically altered the landscape of treatment for various types of malignancy, including colorectal cancer. The category of immune checkpoint inhibitors has especially emerged as a class of therapy predicated on a more comprehensive understanding of immune cell-cancer cell regulation and evolution of the tumor microenvironment over time. Strategies including adoptive cellular therapies, tumor vaccines, and antibodies have also demonstrated the ability to enhance antitumor immunity. Read More

View Article and Full-Text PDF
September 2021

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy.

World J Clin Cases 2021 Jul;9(20):5398-5407

Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb 10000, Croatia.

While pancreatic cancer is still characterized by early systemic spread and poor outcomes, the treatment of this disease has changed significantly in recent years due to major advancements in systemic therapy and advanced surgical techniques. Broader use of effective neoadjuvant approaches combined with aggressive surgical operations within a multidisciplinary setting has improved outcomes. Borderline resectable pancreatic cancer is characterized by tumor vascular invasion, and is a setting where the combination of potent neoadjuvant chemotherapy and aggressive surgical methods, including vascular resections and reconstructions, shows its full potential. Read More

View Article and Full-Text PDF

Does Radiation Dose to Gastric Fundus during Neoadjuvant Chemoradiotherapy for Esophageal Carcinoma Have an Impact on Postoperative Anastomotic Leak?

Gastrointest Tumors 2021 Jun 17;8(3):121-127. Epub 2021 Mar 17.

Department of Surgical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), An Institution of National Importance, Government of India, Puducherry, India.

Background: Radiation dose received by the gastric fundus (GF) in neoadjuvant chemoradiotherapy (NACRT) may influence the development of postoperative anastomotic leak (AL) in the management of resectable esophageal carcinoma (EC) by trimodality therapy. The present study aims to evaluate dose-volume parameters of the GF and their association with occurrence of AL in EC.

Materials And Methods: A retrospective analysis was performed of 27 patients with EC who underwent NACRT followed by esophagectomy with cervical esophagogastric anastomosis between January 2015 and July 2018. Read More

View Article and Full-Text PDF

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.

Front Oncol 2021 9;11:645026. Epub 2021 Jul 9.

Department of Medical Oncology, Institut Català d'Oncologia, IDIBELL, L'Hospitalet, Spain.

Background: The CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other cardiovascular risk factors in whom conventional doxorubicin was contraindicated. The primary analysis of the study showed a pathological complete response (pCR) of 32% and no significant decreases in LVEF during chemotherapy. Here, we report important secondary study objectives: 5-year cardiac safety, disease-free survival (DFS), overall survival (OS) and breast cancer specific survival (BCSS). Read More

View Article and Full-Text PDF

Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma.

J Neurol Surg B Skull Base 2021 Jul 14;82(Suppl 3):e131-e137. Epub 2020 Jan 14.

Department of Otolaryngology Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.

Esthesioneuroblastoma (ENB) is a rare olfactory malignancy that can present with locally advanced disease. At our institution, patients with ENB in whom the treating surgeon believes that a margin-negative resection is initially not achievable are selected to undergo induction with chemotherapy with or without radiotherapy prior to surgery. In a retrospective review of 61 patient records, we identified six patients (10%) treated with this approach. Read More

View Article and Full-Text PDF

The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer.

Iran J Pathol 2021 9;16(3):266-273. Epub 2021 May 9.

Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background & Objective: Currently, neoadjuvant chemoradiotherapy, followed by surgery, is the standard treatment for locally advanced rectal cancer. The use of induction chemotherapy for this tumor is controversial. In this study, the benefits and side effects of induction chemotherapy in locally advanced rectal cancer are evaluated. Read More

View Article and Full-Text PDF

Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy.

Eur J Surg Oncol 2021 Jul 20. Epub 2021 Jul 20.

Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Rui Jin 2nd Road, Shanghai, 200025, China. Electronic address:

Background: To investigate the prognostic value of dual-energy CT (DECT) based radiomics to predict disease-free survival (DFS) and overall survival (OS) for patients with advanced gastric cancer (AGC) after neoadjuvant chemotherapy (NAC).

Methods: From January 2014 to December 2018, a total of 156 AGC patients were enrolled and randomly allocated into a training cohort and a testing cohort at a ratio of 2:1. Volume of interest of primary tumor was delineated on eight image series. Read More

View Article and Full-Text PDF